ClinTec International Expands Further in MENA Region with Proposed Opening of Istanbul Office
News May 22, 2013
ClinTec International, a global CRO with a presence in over 40 countries worldwide, today announced its intention to formally open an office in Istanbul, Turkey. The office will not only provide ClinTec’s global team with access to a new patient population, but will also further consolidate the British CRO’s presence in the Middle East and North Africa (MENA) region. The office adds to the company’s current MENA region offices based in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut, Lebanon.
Speaking at the announcement of ClinTec’s new office, the company’s founder and CEO, Dr Rabinder Buttar commented; “The launch of this new office in Turkey confirms ClinTec International’s reputation as a truly global provider of quality assured clinical research services. It also reflects the growing significance of Turkey- and the wider MENA region- to the global clinical research market. We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole.”
The announcement ClinTec’s new Turkey office coincides with the company sponsoring the Partnerships in Clinical Trials Russia-CIS & MENA-Turkey conference held in Istanbul on 22-23rd May 2013. The conference aims to explore the challenges and opportunities facing companies when conducting clinical trials in the MENA region, and looks for the leading CROs within the region to provide solutions and advice on this complex market. As such, ClinTec’s Executive Vice-President- Global Clinical Development, Bindhya Cariappa, will be delivering a speech on Rare Disease Trials in the MENA region.
“Our sponsorship of the Partnerships in Clinical Trials Russia-CIS & MENA-Turkey Conference, coupled with the opening of the Turkey office, further emphasises our belief that ClinTec’s experienced local management team can easily negotiate the fast-moving and constantly evolving trial environment within the region,” added Dr Buttar.
Tailor-made Protein Fights Several Species of BacteriaNews
As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE